{"name": "enGene",
 "permalink": "engene",
 "crunchbase_url": "http://www.crunchbase.com/company/engene",
 "homepage_url": "http://www.engeneinc.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@engeneinc.com",
 "phone_number": "604-221-4362",
 "description": "",
 "created_at": "Fri Dec 18 11:56:55 UTC 2009",
 "updated_at": "Fri Dec 18 12:08:53 UTC 2009",
 "overview": "\u003Cp\u003EenGene\u00e2\u20ac\u2122s technology, Gut Endocrine-cell Modification System (GEMS), utilizes the\ntherapeutic protein production capacity of existing, normal, healthy cells in a small,\ntargeted area of the duodenum by delivering a gene construct in a novel non-viral vector. For GEMS \u00e2\u20ac\u201cInsulin, this means enabling the patients\u00e2\u20ac\u2122 own cells to produce insulin in a regulated, meal-dependant fashion resulting in physiologic control of blood glucose levels. Other potential applications for GEMS include inflammatory bowel disease, obesity, anemia, and hemophilia.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       43],
      "assets/images/resized/0007/0313/70313v1-max-150x150.jpg"],
     [[181,
       53],
      "assets/images/resized/0007/0313/70313v1-max-250x250.jpg"],
     [[181,
       53],
      "assets/images/resized/0007/0313/70313v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$6.4M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.engeneinc.com/mar_17_08.pdf",
    "source_description": "enGene Inc. completes US$6.4M Series A Financing",
    "raised_amount": 6400000.0,
    "raised_currency_code": "USD",
    "funded_year": 2008,
    "funded_month": 3,
    "funded_day": 17,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Saad Investments Company",
         "permalink": "saad-investments-company",
         "image":
          {"available_sizes":
            [[[150,
               50],
              "assets/images/resized/0007/5051/75051v1-max-150x150.png"],
             [[159,
               54],
              "assets/images/resized/0007/5051/75051v1-max-250x250.png"],
             [[159,
               54],
              "assets/images/resized/0007/5051/75051v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Masa Life Science Fund",
         "permalink": "masa-life-science-fund",
         "image":
          {"available_sizes":
            [[[150,
               76],
              "assets/images/resized/0005/9109/59109v1-max-150x150.jpg"],
             [[250,
               126],
              "assets/images/resized/0005/9109/59109v1-max-250x250.jpg"],
             [[294,
               149],
              "assets/images/resized/0005/9109/59109v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "100-2386 East Mall",
    "address2": "BC",
    "zip_code": "V6T 1Z3",
    "city": "Vancouver",
    "state_code": null,
    "country_code": "CAN",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        83],
       "assets/images/resized/0007/0314/70314v1-max-150x150.jpg"],
      [[250,
        138],
       "assets/images/resized/0007/0314/70314v1-max-250x250.jpg"],
      [[450,
        250],
       "assets/images/resized/0007/0314/70314v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}